VYGR Voyager Therapeutics
- 8.230
- +0.130+1.60%
- 8.300
- +0.070+0.85%
Voyager Therapeutics News
Voyager Therapeutics Analyst Ratings
Voyager Therapeutics: A Buy Rating on the Back of Strategic Advancements and a Promising Alzheimer's Candidate
Voyager Therapeutics Analyst Ratings
Truist Financial Sticks to Its Buy Rating for Voyager Therapeutics (VYGR)
Positive Outlook for Voyager Therapeutics: Buy Rating Affirmed Amid Pipeline Progress and Strong Financial Position
Analysts Have Conflicting Sentiments on These Healthcare Companies: Theravance Biopharma (TBPH), Voyager Therapeutics (VYGR) and Praxis Precision Medicines (PRAX)
Oppenheimer Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)
Optimistic Buy Rating for Voyager Therapeutics Amid Strong Pipeline and Strategic Partnerships
Voyager Therapeutics Analyst Ratings
H.C. Wainwright Initiates Coverage on Voyager Therapeutics With Buy Rating, $30 Price Target
Voyager Therapeutics Analyst Ratings
Voyager Therapeutics: A Buy Rating on Breakthrough CNS Gene Therapy Innovations and Strategic Growth Potential
Voyager Therapeutics Analyst Ratings
Voyager Therapeutics (VYGR) Receives a Rating Update From a Top Analyst
Oppenheimer Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)
Voyager Therapeutics Buy Rating Affirmed Amid Strong Pipeline and Financial Health
Analysts Conflicted on These Healthcare Names: Immunocore Holdings (IMCR), Voyager Therapeutics (VYGR) and Castle Biosciences (CSTL)
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and Warby Parker (WRBY)
Oppenheimer Keeps Their Buy Rating on Voyager Therapeutics (VYGR)
Wedbush Trims Voyager Therapeutics' Price Target to $10 From $11, Neutral Rating Kept
Analysis
Price Target
No Data
